Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late-breaking research presented in a Hot Line session ...

Modern treatments for heart failure (HF) patients with low ejection fraction (EF), which indicates systolic function impairments in the cardiovascular system, may improve EF. However, data on managing ...

Treatment with dapagliflozin reduced the risk of death or worsening heart failure by 28% compared with standard of care. Dapagliflozin reduced the risk of death or worsening heart failure (HF) in ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

The National Institute for Health and Care Excellence (NICE) has extended its recommended indications for dapagliflozin (Forxiga, AstraZeneca) to include adults with symptomatic chronic heart failure ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The placebo-controlled, event-driven DELIVER study included 6263 patients.

Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for ...

Early initiation of dapagliflozin does not appear to interfere with diuretic treatment for heart failure. (HealthDay News) — For patients with acute heart failure (AHF), early initiation of ...

Additional analyses of recent dapagliflozin trials should help clinicians understand the best ways to implement them in practice, as well as their expected benefits, researchers said at the recent ...

The DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18 facilities in Japan. In this study, we investigated ...